Genelux Corporation
GNLX · Nasdaq · United States
Share price · GNLX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when GNLX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 18 Nov 2026+12.0%
- 21 Oct 2026-17.2%
Nothing announced by GNLX that day or the session before.
- 14 Oct 2026-7.9%
Nothing announced by GNLX that day or the session before.
- 5 Aug 2026-11.0%
Nothing announced by GNLX that day or the session before.
- 4 Aug 2026-5.4%
Nothing announced by GNLX that day or the session before.
- 17 Jun 2026-5.9%
Nothing announced by GNLX that day or the session before.
- 11 May 2026-6.8%
Nothing announced by GNLX that day or the session before.
- 8 May 2026+9.9%
- 15 Apr 2026+7.6%
Nothing announced by GNLX that day or the session before.
- 8 Jan 2026-19.8%
Share of unusual movement by asset
For each asset, the share of GNLX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | No discrete molecular targetOncolytic virus | Non-Small Cell Lung CancerOvarian Cancer |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (1)
February 2027 (1)
What to watch
Financial reports
Quarterly & interim (14)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $6.5M | $9.2M+ $9.5M short-term inv. | $9.5M-$6.4M operating cash flow | report ↗ |
View 13 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | — | $5.8M | $9.3M+ $17M short-term inv. | $8.9M-$6.1M operating cash flow | report ↗ |
| 2025-Q3 | — | $4.7M | $4.7M+ $16M short-term inv. | $8.0M-$6.6M operating cash flow | report ↗ |
| 2025-Q2 | — | $4.8M | $6.5M+ $21M short-term inv. | $7.5M-$7.1M operating cash flow | report ↗ |
| 2025-Q1 | — | $4.7M | $16M+ $19M short-term inv. | $7.5M-$5.4M operating cash flow | report ↗ |
| 2024-Q3 | — | $4.0M | $6.1M+ $28M short-term inv. | $6.5M-$5.8M operating cash flow | report ↗ |
| 2024-Q2 | — | $4.4M | $7.9M+ $26M short-term inv. | $6.6M-$6.8M operating cash flow | report ↗ |
| 2024-Q1 | <$0.1M | $4.0M | $4.1M+ $16M short-term inv. | $7.8M-$4.3M operating cash flow | report ↗ |
| 2023-Q3 | — | $2.8M | $30M | $5.3M-$3.4M operating cash flow | report ↗ |
| 2023-Q2 | — | $2.9M | $27M | $5.8M-$5.4M operating cash flow | report ↗ |
| 2023-Q1 | $0.2M | $2.9M | $10M | $10M-$4.6M operating cash flow | report ↗ |
| 2022-Q3 | $11M | $2.4M | $1.4M | —-$2.5M operating cash flow | report ↗ |
| 2022-Q2 | — | $1.8M | $4.2M | $2.8M-$2.4M operating cash flow | report ↗ |
| 2022-Q1 | — | $2.4M | $7.2M | $3.8M$2.8M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | <$0.1M | $20M | $5.3M | $8.0M-$25M operating cash flow | report ↗ |
For fiscal year 2025, Genelux reported revenue of $0.01M, up 0.0% YoY, and R&D spend of $19.85M, up 4.5% YoY. Cash and equivalents stood at $5.33M, with a net loss of $32.15M and a quarterly net burn of $32.15M.
Genelux is advancing its lead oncolytic viral immunotherapy candidate, Olvi-Vec, through a Phase 3 registrational trial (OnPrime/GOG-3076) in platinum-resistant/refractory ovarian cancer, a Phase 2 trial (VIRO-25) in recurrent non-small cell lung cancer, and a Phase 1b/2 trial in recurrent small cell lung cancer in China. Initial interim results as of December 2025 data cutoffs showed a 60% disease control rate in five evaluable VIRO-25 patients and a 33% overall response rate (3/9 patients) in the SCLC trial, with Olvi-Vec generally well tolerated. Management anticipates reporting Phase 3 topline results in the second half of 2026 and updated dose-finding data throughout 2026, and the company continues its collaboration with Newsoara under a license agreement covering Olvi-Vec development in China.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | <$0.1M | $19M | $8.6M+ $22M short-term inv. | $7.5M-$21M operating cash flow | report ↗ |
| 2023-FY | $0.2M | $13M | $9.4M+ $14M short-term inv. | $7.1M-$20M operating cash flow | report ↗ |
| 2022-FY | $11M | $9.1M | $0.4M | $1.3M-$3.6M operating cash flow | report ↗ |
| 2021-FY | — | — | $4.5M | — | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 24 sales ($341K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-03 | Yu Yong · Chief Scientific Officer | Open-market sale | 668 | $2.01 | $1K | Form 4 |
| 2026-11-03 | Zindrick Thomas · President and CEO | Open-market sale | 3,089 | $2.05 | $6K | Form 4 |
| 2026-11-03 | Cappello Joseph · Chief Technical Officer | Open-market sale | 668 | $2.04 | $1K | Form 4 |
| 2026-08-31 | Yu Yong · Chief Scientific Officer | Open-market sale | 9,683 | $2.75 | $27K | Form 4 |
| 2026-08-31 | Zindrick Thomas · President and CEO | Open-market sale | 34,463 | $2.67 | $92K | Form 4 |
| 2026-08-31 | Cappello Joseph · Chief Technical Officer | Open-market sale | 10,257 | $2.74 | $28K | Form 4 |
| 2026-08-04 | Zindrick Thomas · President and CEO | Open-market sale | 3,023 | $2.95 | $9K | Form 4 |
| 2026-08-04 | Cappello Joseph · Chief Technical Officer | Open-market sale | 653 | $2.95 | $2K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 70 reporting institutions held 9.3M shares ($23.3M, 20.5% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | WOODWARD DIVERSIFIED CAPITAL, LLC | 2,117,183 | $5.9M |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 1,695,480 | $4.1M |
| 3 | Bleichroeder LP | 1,380,666 | $3.3M |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 453,761 | $1.1M |
| 5 | BlackRock, Inc. | 405,872 | $982K |
| 6 | BANK OF AMERICA CORP /DE/ | 323,865 | $784K |
| 7 | FLPUTNAM INVESTMENT MANAGEMENT CO | 280,904 | $680K |
| 8 | VANGUARD FIDUCIARY TRUST CO | 251,610 | $609K |
| 9 | CM Management, LLC | 250,000 | $605K |
| 10 | NORTHERN TRUST CORP | 164,456 | $398K |
| 11 | Provident Wealth Management, LLC | 155,670 | $377K |
| 12 | STATE STREET CORP | 145,850 | $353K |
| 13 | LPL Financial LLC | 139,041 | $336K |
| 14 | UBS Group AG | 122,579 | $297K |
| 15 | OSAIC HOLDINGS, INC. | 119,008 | $288K |